## CLAIMS

1. (currently amended) A compound of Formula ~~I(i) or I(j):~~



~~I(i) or~~



~~I(j)~~



or



or a pharmaceutically acceptable salt thereof, wherein:

$R^1$ is $C_6$-$C_{10}$ aryl substituted with 0-3 $R^{1a}$, or a $C_3$-$C_8$ cycloalkyl substituted with 0-2 $R^{1b}$, wherein said $C_3$-$C_8$ cycloalkyl is saturated or unsaturated;

each $R^{1a}$ is independently a member selected from the group consisting of H, $C_1$-$C_3$ perfluoroalkyl, $C_3$-$C_7$ cycloalkyl, F, Cl, Br, CN, $NO_2$, $OR^{10}$, $SCH_3$, $S(=O)CH_3$, $S(=O)_2R^{10}$, $NR^{11}R^{12}$, acetyl, $C(=O)OR^{13}$, $C(=O)NR^{13}R^{14}$, $S(=O)_2NR^{13}R^{14}$, phenyl substituted with 0-3 $R^{15}$, and a $C_1$-$C_4$ alkyl substituted with 0-2 $R^{16}$;

each $R^{1b}$ is independently a member selected from the group consisting of H, OH, F, Cl, acetyl, =O, $C_1$-$C_6$ alkyl, $C_1$-$C_6$ alkoxy, $CF_3$ and $OCF_3$;

$R^2$ is a member selected from the group consisting of a phenyl substituted with 0-3 $R^{15}$, a $C_1$-$C_6$ alkyl substituted with 0-2 $R^{2a}$, a $C_2$-$C_6$ alkenyl, a $C_2$-$C_6$ alkynyl, a $C_3$-$C_7$ cycloalkyl substituted with 0-2 $R^{19}$, and a $C_7$-$C_{11}$ bicycloalkyl substituted with 0-2 $R^{19}$;

each $R^{2a}$ is independently a member selected from the group consisting of a $C_6$-$C_{10}$ aryl substituted with 0-3 $R^{15}$, a $C_3$-$C_8$ cycloalkyl substituted with 0-2 $R^{19}$, and a $C_7$-$C_{11}$ bicycloalkyl substituted with 0-2 $R^{19}$;

~~$R^3$ is a member selected from the group consisting of H and $C_1$-$C_4$ alkyl;~~

$R^5$ is a member selected from the group consisting of H, $C_3$-$C_7$ cycloalkyl, $C_2$-$C_6$ alkenyl, $C_2$-$C_6$ alkyne, phenyl substituted with 0-2 $R^{15}$; and a $C_1$-$C_6$ alkyl substituted with 0-2 $R^{18}$;

~~each of $R^6$, $R^7$, and $R^8$ is independently a member selected from the group consisting of H and $C_1$-$C_4$ alkyl;~~

each $R^{10}$ is independently a member selected from the group consisting of H, $C_3$-$C_7$ cycloalkyl, a $C_1$-$C_3$ perfluoroalkyl, a $C_1$-$C_4$ alkyl substituted with 0-1 $R^{25}$, and a phenyl substituted with 0-3 $R^{15}$;

each $R^{11}$ is independently a member selected from the group consisting of H, $^t$BOC, Cbz, $C_3$-$C_8$ cycloalkyl, ($C_1$-$C_6$ alkyl)-C(=O)-, ($C_1$-$C_6$ alkyl)-S(=O)$_2$- and a $C_1$-$C_6$ alkyl;

each of $R^{12}$, $R^{13}$ and $R^{14}$ is independently a member selected from the group consisting of H and $C_1$-$C_4$ alkyl;

each $R^{15}$ is independently a member selected from the group consisting of H, OH, F, Cl, Br, I, CN, $NO_2$, $COOR^{13}$, $C(=O)NR^{13}R^{14}$, $S(=O)_2NR^{13}R^{14}$, acetyl, $-SCH_3$, $-S(=O)CH_3$, $-S(=O)_2CH_3$, $NR^{26}R^{27}$, $C_1$-$C_6$ alkoxy, $C_1$-$C_3$ perfluoroalkyl, $C_1$-$C_3$ perfluoroalkoxy and a $C_1$-$C_6$ alkyl;

each $R^{16}$ is independently a member selected from the group consisting of H, OH, $COOR^{13}$, $C(=O)NR^{13}R^{14}$, $S(=O)_2NR^{13}R^{14}$, acetyl, $-SCH_3$, $-S(=O)CH_3$, $-S(=O)_2CH_3$, $C_1$-$C_6$ alkoxy, $NR^{26}R^{27}$, and a phenyl substituted with 0-3 $R^{15}$;

each $R^{18}$ is independently a member selected from the group consisting of H, OH, F, Cl, CN, $NO_2$, $C(=O)OR^{30}$, $C(=O)NR^{13}R^{14}$, $NR^{11}R^{12}$, a $C_1$-$C_3$ perfluoroalkyl, a $C_1$-$C_3$ perfluoroalkoxy, a phenyl substituted with 0-3 $R^{15}$; and $C_3$-$C_8$ cycloalkyl;

each $R^{19}$ is independently a member selected from the group consisting of $C_1$-$C_4$ alkyl, F, Cl, $C_1$-$C_4$ alkoxy, $CF_3$ and $OCF_3$;

$R^{23}$ is a bond, H, F, OH, $C_1$-$C_4$ alkyl, and $C_1$-$C_3$ alkylhydroxy;

each $R^{25}$ is independently a member selected from the group consisting of H, $C_3$-$C_7$ cycloalkyl, and a phenyl substituted with 0-3 $R^{15}$;

each $R^{26}$ is independently a member selected from the group consisting of H, $C_1$-$C_4$ alkyl, ($C_1$-$C_4$ alkyl)-C(=O)- and ($C_1$-$C_4$ alkyl)-S(=O)$_2$-;

each $R^{27}$ is independently a member selected from the group consisting of H and $C_1$-$C_4$ alkyl;

each $R^{28}$ is independently a member selected from the group consisting of H, a $C_1$-$C_6$ alkyl, $C_3$-$C_8$ cycloalkyl, a phenyl substituted with 0-3 $R^{15}$, and a benzyl substituted with 0-2 $R^{15}$;

each $R^{29}$ is independently a member selected from the group consisting of H, F, Cl, Br, I, CN, $NO_2$, $OR^{28}$, $SR^{28}$, $S(=O)R^{28}$, $S(=O)_2R^{28}$, $S(=O)_2NR^{13}R^{14}$, $NR^{26}R^{27}$, acetyl, $C(=O)NR^{13}R^{14}$, $C(=O)OR^{13}$, $C_1$-$C_6$ alkyl, $OCHF_2$, $SCF_3$, $OCF_3$, and $-C(=NH)NH_2$; and

each $R^{30}$ is independently a member selected from the group consisting of H, $C_3$-$C_7$ cycloalkyl, $C_1$-$C_4$ alkyl substituted with 0-1 $R^{25}$, and a phenyl substituted with 0-3 $R^{15}$;

~~and with the proviso that $R^3$, $R^5$, $R^6$, $R^7$, and $R^8$ are not all hydrogen.~~

2-3. (canceled)

4. (previously presented) The compound of claim 1, wherein $R^1$ is phenyl substituted with 0-3 $R^{1a}$.

5-6. (canceled)

7. (previously presented) The compound of claim 9 wherein:

$R^1$ is $C_3$-$C_8$ cycloalkyl substituted with 0-2 $R^{1b}$, wherein said $C_3$-$C_8$ cycloalkyl is saturated or unsaturated; and

$R^2$ is a member selected from the group consisting of a phenyl substituted with 0-3 $R^{15}$, a $C_1$-$C_6$ alkyl substituted with 0-2 $R^{2a}$, and a $C_3$-$C_7$ cycloalkyl substituted with 0-2 $R^{19}$.

8. (previously presented) The compound of claim 9, wherein:

$R^2$ is a member selected from the group consisting of a $C_1$-$C_2$ alkyl substituted with 1 $R^{2a}$, and $C_1$-$C_6$ alkyl;

each $R^{2a}$ is independently a member selected from the group consisting of a phenyl substituted with 0-3 $R^{15}$, and a $C_3$-$C_8$ cycloalkyl substituted with 0-2 $R^{19}$;

$R^5$ is a member selected from the group consisting of H, $C_3$-$C_7$ cycloalkyl; and a $C_1$-$C_6$ alkyl substituted with 0-1 $R^{18}$; and

each $R^{18}$ is independently a member selected from the group consisting of H, OH, F, Cl, CN, $C(=O)OR^{30}$, $C(=O)NR^{13}R^{14}$, $NR^{11}R^{12}$, a phenyl substituted with 0-3 $R^{15}$, and $C_3$-$C_8$ cycloalkyl.

9. (previously presented) The compound of claim 1, wherein said compound is of the formula:



10-15. (canceled)

16. (previously presented) The compound of claim 18 wherein:

$R^1$ is $C_6$-$C_{10}$ aryl substituted with 0-3 $R^{1a}$; and

each $R^{1a}$ is independently a member selected from the group consisting of H, $C_1$-$C_3$ perfluoroalkyl, $C_3$-$C_7$ cycloalkyl, F, Cl, Br, CN, $NO_2$, $OR^{10}$, $SCH_3$, $S(=O)CH_3$, $S(=O)_2R^{10}$, $NR^{11}R^{12}$, acetyl, $C(=O)OR^{13}$, $C(=O)NR^{13}R^{14}$, $S(=O)_2NR^{13}R^{14}$, phenyl substituted with 0-3 $R^{15}$, and a $C_1$-$C_4$ alkyl substituted with 0-2 $R^{16}$.

17. (previously presented) The compound of claim 18, wherein:

$R^2$ is a member selected from the group consisting of a $C_1$-$C_2$ alkyl substituted with 1 $R^{2a}$, and $C_1$-$C_6$ alkyl;

each $R^{2a}$ is independently a member selected from the group consisting of a phenyl substituted with 0-3 $R^{15}$, and a $C_3$-$C_8$ cycloalkyl substituted with 0-2 $R^{19}$; and

$R^5$ is a member selected from the group consisting of H, $C_3$-$C_7$ cycloalkyl; and a $C_1$-$C_6$ alkyl.

18. (previously presented) The compound of claim 1, wherein said compound is of the formula:



19. (previously presented) The compound of claim 9 wherein:

$R^1$ is $C_6$-$C_{10}$ aryl substituted with 0-3 $R^{1a}$;

each $R^{1a}$ is independently a member selected from the group consisting of H, $C_1$-$C_3$ perfluoroalkyl, $C_3$-$C_7$ cycloalkyl, F, Cl, Br, CN, $NO_2$, $OR^{10}$, $SCH_3$, $S(=O)CH_3$, $S(=O)_2R^{10}$, $NR^{11}R^{12}$, acetyl, $C(=O)OR^{13}$, $C(=O)NR^{13}R^{14}$, $S(=O)_2NR^{13}R^{14}$, phenyl substituted with 0-3 $R^{15}$; and a $C_1$-$C_4$ alkyl substituted with 0-2 $R^{16}$;

$R^2$ is a member selected from the group consisting of a phenyl substituted with 0-3 $R^{15}$; a $C_1$-$C_2$ alkyl substituted with 1 $R^{2a}$, and a $C_3$-$C_7$ cycloalkyl substituted with 0-2 $R^{19}$; and

each $R^{2a}$ is independently a member selected from the group consisting of a $C_6$-$C_{10}$ aryl substituted with 0-3 $R^{15}$; a $C_3$-$C_8$ cycloalkyl substituted with 0-2 $R^{19}$; and a $C_7$-$C_{11}$ bicycloalkyl substituted with 0-2 $R^{19}$.

20-26. (canceled)

27. (currently amended) A pharmaceutical composition comprising the compound of [[~~Formula I(i) or I(j) in claim 1~~]] claim 9 and a pharmaceutically acceptable excipient.

28. (previously presented) A pharmaceutical composition comprising the compound of claim 38 and a pharmaceutically acceptable excipient.

29-37. (canceled)

38. (currently amended) The compound of claim 1, selected from the group consisting of:

(S)-N-{1-[2-(5-Fluoro-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-3-methyl-butyl}-3-methyl-benzamide;

N-(S)-{2-cyclohexyl-1-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-ethyl}-4-phenoxy-benzamide;

(S)-3-Cyclohexyl-N-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethyl]-2-[2-(4-methoxy-phenyl)-acetylamino]-propionamide;

(S)-N-{1-[2-(5-Chloro-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-3-methyl-butyl}-3-methyl-benzamide;

(S)-N-{3-Cyclohexyl-1-[2-(7-methoxy-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-propyl}-3-methoxy-benzamide;

(S)-N-{3-Cyclohexyl-1-[2-(6-fluoro-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-propyl}-3-methoxy-benzamide;

(S)-N-{3-Cyclohexyl-1-[2-(7-fluoro-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-propyl}-3-methoxy-benzamide;

(S)-N-{3-Cyclohexyl-1-[2-(5-cyano-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-propyl}-3-methoxy-benzamide;

Cyclopropanecarboxylic acid (S)-{2-cyclohexyl-1-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-ethyl}-amide;

(S)-N-{3-Cyclohexyl-1-[2-(4-methoxy-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-propyl}-3-methoxy-benzamide;

(S)-N-{3-Cyclohexyl-1-[2-(5-methoxy-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-propyl}-3-methoxy-benzamide;

(S)-N-{3-Cyclohexyl-1-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-propyl}-3-methoxy-benzamide;

(S)-N-{3-Cyclohexyl-1-[2-(5-benzyloxy-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-propyl}-3-methoxy-benzamide;

~~N-{(1S)-[2-(5-Fluoro-2,3-dihydro-indol-1-yl)-1,1-dimethyl-ethylcarbamoyl]-2-phenyl-ethyl}-3-methyl-benzamide;~~

*N*-{3-Cyclohexyl-1-(S)-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-1-(R)-hydroxymethyl-ethylcarbamoyl]-propyl}-3-methoxy-benzamide;

*N*-{3-Cyclohexyl-1-(R)-[(S)-2-(5-fluoro-2,3-dihydro-indol-1-yl)-1-(R)-hydroxymethyl-ethylcarbamoyl]-propyl}-3-methoxy-benzamide;

(S,S)-5-(5-Fluoro-2,3-dihydro-indol-1-yl)-4-[4-methyl-2-(3-methyl-benzoylamino)-pentanoylamino]-pentanoic acid benzyl ester;

(S,S)-5-(5-Fluoro-2,3-dihydro-indol-1-yl)-4-[4-methyl-2-(3-methyl-benzoylamino)-pentanoylamino]-pentanoic acid;

(S,S)-*N*-{1-[3-Carbamoyl-1-(5-fluoro-2,3-dihydro-indol-1-ylmethyl)-propylcarbamoyl]-3-methyl-butyl}-3-methyl-benzamide;

(S,S)-3-[4-Cyclohexyl-2-(3-methoxy-benzoylamino)-butyrylamino]-4-(5-fluoro-2,3-dihydro-indol-1-yl)-butyric acid benzyl ester;

(S,S)-3-[4-Cyclohexyl-2-(3-methoxy-benzoylamino)-butyrylamino]-4-(5-fluoro-2,3-dihydro-indol-1-yl)-butyric acid;

(S,S)-N-{1-[1-Benzyl-2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-3-cyclohexyl-propyl}-3-methoxy-benzamide;

(S,S)-N-{3-Cyclohexyl-1-[1-(5-fluoro-2,3-dihydro-indol-1-ylmethyl)-3-methyl-butylcarbamoyl]-propyl}-3-methoxy-benzamide;

(S,S)-*N*-{3-Cyclohexyl-1-[1-(5-fluoro-2,3-dihydro-indol-1-ylmethyl)-2-methyl-propylcarbamoyl]-propyl}-3-methoxy-benzamide;

(S,S)-*N*-{3-Cyclohexyl-1-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-1-phenyl-ethylcarbamoyl]-propyl}-3-methoxy-benzamide;

N-{2-cyclohexyl-1-(S)-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-ethyl}-2-(2-fluoro-biphenyl-4-yl)-propionamide;

N-{2-cyclohexyl-1-(S)-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-ethyl}-2-p-tolyl-propionamide;

N-{2-cyclohexyl-1-(S)-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-ethyl}-2-o-tolyl-propionamide;

N-{2-cyclohexyl-1-(S)-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-ethyl}-2-(4-fluoro-phenyl)-propionamide;

2-(4-Chloro-phenyl)-N-{2-cyclohexyl-1-(S)-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-ethyl}-propionamide;

N-{2-cyclohexyl-1-(S)-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-ethyl}-2-(R)-phenyl-propionamide;

N-(S)-{2-cyclohexyl-1-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-ethyl}-3-methyl-benzamide;

N-(S)-{2-cyclohexyl-1-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-ethyl}-4-(methanesulfonylamino-methyl)-benzamide;

N-(S)-{2-cyclohexyl-1-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-ethyl}-3-methanesulfonyl-benzamide;

N-(S)-{2-cyclohexyl-1-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-ethyl}-4-methanesulfonylamino-benzamide;

N-{2-cyclohexyl-1-(S)-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-ethyl}-2-(4-hydroxy-phenyl)-propionamide;

4-Cyclohexyl-N-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethyl]-2-(S)-(2-(R)-phenyl-propionylamino)-butyramide;

N-{2-cyclohexyl-1-(S)-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-ethyl}-2-(R)-phenyl-butyramide;

N-{2-Cyclohexyl-1-(S)-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-1-(R)-hydroxymethyl-ethylcarbamoyl]-ethyl}-3-methoxy-benzamide;

N-{1-(S)-[2-(5-Fluoro-2,3-dihydro-indol-1-yl)-1-(R)-hydroxymethyl-ethylcarbamoyl]-3,3-dimethyl-butyl}-3-methoxy-benzamide;

4-(5-Fluoro-2,3-dihydro-indol-1-yl)-3-(S)-[2-(S)-(3-methoxy-benzoylamino)-4,4-dimethyl-pentanoylamino]-butyric acid tert-butyl ester;

3-(S)-[3-Cyclohexyl-2-(S)-(3-methoxy-benzoylamino)-propionylamino]-4-(5-fluoro-2,3-dihydro-indol-1-yl)-butyric acid benzyl ester;

3-(S)-[3-Cyclohexyl-2-(S)-(3-methoxy-benzoylamino)-propionylamino]-4-(5-fluoro-2,3-dihydro-indol-1-yl)-butyric acid;

4-(5-Fluoro-2,3-dihydro-indol-1-yl)-3-(S)-[2-(S)-(3-methoxy-benzoylamino)-4,4-dimethyl-pentanoylamino]-butyric acid ethyl ester;

N-{1-(S)-[2-Cyano-1-(S)-(5-fluoro-2,3-dihydro-indol-1-ylmethyl)-ethylcarbamoyl]-3,3-dimethyl-butyl}-3-methoxy-benzamide;

N-{1-(S)-[5-Amino-1-(S)-(5-fluoro-2,3-dihydro-indol-1-ylmethyl)-pentylcarbamoyl]-3-cyclohexyl-propyl}-3-methoxy-benzamide;

(S,S)-N-{3-Cyclohexyl-1-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-1-(4-hydroxy-benzyl)-ethylcarbamoyl]-propyl}-3-methoxy-benzamide;

Cyclopropanecarboxylic acid {1-(*S*)-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-1-(*S*)-methyl-ethylcarbamoyl]-3,3-dimethyl-butyl}-amide;

N-((S)-(2-(5-fluoroindolin-1-yl)ethylcarbamoyl)(cyclohexyl) methyl)-3-methylbenzamide;

N-((S)-1-(2-(5-fluoroindolin-1-yl)ethylcarbamoyl)-2-(2-chlorophenyl)ethyl)-3-methylbenzamide;

N-((S)-1-(2-(5-fluoroindolin-1-yl)ethylcarbamoyl)-2-(3-chlorophenyl)ethyl)-3-methylbenzamide;

N-((S)-1-(2-(5-fluoroindolin-1-yl)ethylcarbamoyl)-2-(4-chlorophenyl)ethyl)-3-methylbenzamide;

(S)-N-{2-Cyclopentyl-1-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-ethyl}-3-methyl-benzamide;

N-((S)-1-(2-(5-fluoroindolin-1-yl)ethylcarbamoyl)-3,3-dimethylbutyl)-3-methylbenzamide;

N-((S)-1-(2-(5-fluoroindolin-1-yl)ethylcarbamoyl)-3-cyclohexylpropyl)-3-methylbenzamide;

N-((S)-1-(2-(5-fluoroindolin-1-yl)ethylcarbamoyl)-2-phenylethyl)-3-methylbenzamide;

N-(R,S)-((3-(5-fluoroindolin-1-yl)-1-hydroxypropan-2-(R)-ylcarbamoyl)(2,4-dichlorophenyl)methyl)-3,4-difluorobenzamide;

(R,S)-N-((2-(5-fluoroindolin-1-yl)ethylcarbamoyl)(2,4-dichlorophenyl)methyl)-3-methylbenzamide;

(S,S)-N-((3-(5-fluoroindolin-1-yl)-1-hydroxypropan-2-ylcarbamoyl)(2,4-dichlorophenyl)methyl)-3,4-difluorobenzamide;

(S,S)-4-(5-Fluoro-2,3-dihydro-indol-1-yl)-3-[2-(3-methoxy-benzoylamino)-4,4-dimethyl-pentanoylamino]-butyric acid; and

(S,S)-N-{3-Cyclohexyl-1-[1-(5-fluoro-2,3-dihydro-indol-1-ylmethyl)-3-hydroxy-propylcarbamoyl]-propyl}-3-methoxy-benzamide.

39. (new) A pharmaceutical composition comprising the compound of claim 18, and a pharmaceutically acceptable excipient.

40. (new) N-{(1S)-[2-(5-Fluoro-2,3-dihydro-indol-1-yl)-1,1-dimethyl-ethylcarbamoyl]-2-phenyl-ethyl}-3-methyl-benzamide.

41. (new) The compound of claim 40, and a pharmaceutically acceptable excipient.